TIRZEPATIDE
- ≥99 % Reinheit per HPLC
- Janoshik-COA zu jeder Charge
- Chargenrückverfolgung ab Synthese
- In der EU synthetisiert
Spezifikationen
Unabhängig im Labor geprüft
Jede Charge wird von Janoshik Analytical unabhängig per HPLC geprüft. Das COA ist chargenspezifisch und stammt vom prüfenden Labor.
Lagerung & Handhabung
Lyophilisierte Peptide sollten bis zu 24 Monate unter 16 °C sowie licht- und feuchtigkeitsgeschützt gelagert werden. Nach der Rekonstitution gekühlt lagern und innerhalb von 30 Tagen verwenden.
Rekonstitution
2mL bacteriostatic water for injection (BWI). Yields 5mg per 1.0mL.
The dual agonist
benchmark.
Tirzepatide is the most-studied GLP-1 / GIP dual agonist in metabolic research. Activating both receptors simultaneously produces a steeper glycemic response curve and stronger satiety signaling than GLP-1 alone - the basis for nearly every modern incretin-mimetic protocol design.
Lot-to-lot reproducibility is the primary reason researchers source TIRZEPATIDE from us. Each lot is HPLC-MS verified at ≥99% purity by Janoshik Analytical, with full sequence and mass-match documentation in the Certificate of Analysis.
| Verbindung | Tirzepatide |
|---|---|
| Sequenzlänge | 39 amino acids |
| Molekulare Masse | 4813.5 Da |
| Modellierte Halbwertszeit | ~5 days (modeled) |
| Mechanismus / Forschungsklasse | Dual GLP-1R / GIPR agonist. |
| Lösungsmittel für die Laborhandhabung | 2mL bacteriostatic water for injection (BWI) |
| Berechnete Konzentration | Yields 5mg per 1.0mL |
| Lieferformat | Tirzepatide · 10MG · GLP-1/GIP lyophilisiertes Forschungsvial |
Synthetisiert.
Verifiziert.
Dokumentiert.
Durch Forschung gestützt.
In Ergebnissen messbar.
Jedes Themenfeld führt zur zitierten Literatur. Die Referenzen sind mit PubMed verlinkt.
Tirzepatide is a 39-amino-acid GLP-1 / GIP dual agonist. The dual receptor profile produces a steeper satiety-pathway response than single-pathway GLP-1, with downstream effects on body weight and adiposity in both research models and published clinical literature.
The reference SURMOUNT-1 trial reported a mean body-weight reduction of −22.5% from baseline at 72 weeks in the highest published study arm, with monotonic responses across published study arms. Results referenced for in-vitro / animal-model protocol design only.
GLP-1 / GIP dual agonism amplifies insulin secretion and steepens the glycemic-response curve compared with single-pathway GLP-1 agonism. The reference literature reports HbA1c reductions of 1.87% to 2.59% across published weekly study arms in T2D research populations.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. The Lancet. 2021;398(10295):143-155.PubMed ↗
GLP-1 / GIP co-agonism engages hepatic lipid handling beyond what GLP-1 alone produces. The Tirzepatide MASLD substudy reported relative liver-fat reduction of up to 73% at 52 weeks measured by MRI-PDFF in the highest published study arm.
- Hartman ML et al. Effects of tirzepatide on biomarkers of NAFLD/NASH in patients with T2D. Diabetes Care. 2020;43(6):1352-1355.PubMed ↗
Beyond direct glycemic effects, dual incretin agonism improves measured markers of insulin sensitivity (HOMA-IR) and metabolic flexibility in research populations - a profile that distinguishes Tirzepatide from single-pathway references in published comparison studies.
- Frías JP et al. SURPASS-2 trial. NEJM. 2021;385(6):503-515.PubMed ↗
M. Virtanen –
Third order from NZM. HPLC purity on the COA matched the lot number on the vial exactly — our QC ran independent verification and the numbers lined up within margin.
A. Keller –
Cold-chain packaging done properly, vials arrived sealed with intact stoppers. Reconstitution in bacteriostatic water was clean, no visible particulates.
S. Lindqvist –
Fast dispatch to Sweden. Documentation for institutional purchasing was handled without friction — invoice, COA and lot traceability all in order.
J. Novak –
Vial labelling is clear and the lot lookup works as advertised. One spec field on the datasheet was still marked pending, which we would like to see filled in.
L. De Vries –
Ordered for a receptor-binding assay panel. Lyophilized cake was uniform and dissolved rapidly. Mass spec on our end confirmed identity.
R. Holm –
Ordered TIRZEPATIDE for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
E. Kowalski –
Procurement was straightforward as a lab customer. VAT invoice issued correctly, delivery to Poland in five working days.
T. Bergström –
Consistent between lots so far — three separate lots ordered and the COAs have stayed within tight purity bands.
C. Meyer –
Solid supplier. Packaging generous for the vial count. Minor gripe: tracking updates lagged a day behind actual transit.
P. Jansen –
The independent third-party COA is the reason we switched suppliers. Lot number searchable, report legible, no account needed.
K. Tamm –
Shipped to Estonia without customs friction. Vials arrived well within the stated transit window, contents in spec on arrival.
N. Fischer –
Reordered after an initial trial batch. Reconstituted solution stayed clear under refrigeration across the study window.
O. Nielsen –
Support answered a technical question about storage temperature the same day, with a reference instead of marketing language.
H. Wagner –
Product itself checks out — purity as stated. Delivery took nine days to Austria after a customs hold, longer than the estimate. Would order again but plan margins accordingly.
D. Laine –
Clean COA, accurate fill volumes, sensible packaging. Exactly what a research supplier should be: boring in the best way.
G. Rossi –
First order as an independent researcher. The verification portal and lot traceability gave enough confidence to proceed; the material matched documentation.
F. Dubois –
We compared three EU suppliers this quarter. NZM documentation and lot consistency were the differentiator.
I. Petrov –
Good material and fast handling. The spec table still has a few fields pending, which matters for our SOPs — support filled the gap by email.
V. Andersen –
Repeat institutional order. Temperature indicators in the shipment showed no excursion; QC accepted the lot without deviation.